CD8+ T cells are the main cells for the tumor-specific immune response and have achieved initial clinical success in several cancers, including melanoma, renal cell carcinoma, and Hodgkin’s lymphoma [51,52]. This evidence concerns the gene CD8A and renal cell carcinoma.